EFFECT OF POTENTIAL INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 1 ON THE FUNCTIONAL-METABOLIC PARAMETERS IN RATS WITH EXPERIMENTAL TYPE 2 DIABETES MELLITUS

Authors

  • Krasova N. S. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Gladkih A. I. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Lipson V. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Leshchenko Z. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Tyzhnenko T. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Opaleiko Y. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Zubatyuk T. SSI «Institute for Single Crystals» of NAS of Ukraine, Kharkiv
  • Svidlo I. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Yaremenko F. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Poltorak V. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2014.4.07

Keywords:

type 2 diabetes mellitus, 11β-hydroxysteroid dehydrogenase type 1 inhibitor, insulin resistance, obesity

Abstract

It has been established that the intragastric administration within 15 days of the heterocyclic compound AD-1408 — a potential enzyme inhibitor prereceptor exchange corticosteroids — 11β-hydroxysteroid dehydrogenase type 1 leads to improvement of glucose tolerance, increased of insulin sensitivity, reduced of blood pressure and weight of abdominal fat fractions in sexually mature Wistar male rats with experimental type 2 diabetes and obesity. The studied compound was not inferior and sometimes even exceeded by the effectiveness of influence than the effect of the reference drug metformin.

References

Blucher M. Exp Clin Endocrinol Diab 2009;117(6):241-250.

Bezverha TP, Tron’ko MD. Endokrynologija 2008; 13(1):117-135.

Stewart PM, Toogood AA, Tomlinson JW. Horm Res 2001; 56:1-6.

Stewart PM. Clin Med 2005; 5:142-146.

Morton NM, Seckl JR. Front Horm Res 2008;36:146-164.

Stomby A, Andrew R, Walker BR, Olsson T. Diabetologia 2014; 57: 1100-1110.

Wamil M, Seckl JR. Drug Discovery Today 2007; 12:504-520.

Fotsch C, Wang M. J Med Chem 2008; 51:4851-4857.

Pereira CD, Azevedo I, Monteiro R, Martins MJ. Diabetes Obes Metab 2012; 14:869-891.

Jurgoński A, Juśkiewicz J, Zduńczyk Z. Nutrients 2014; 6(2):616-626.

Zapadnjuk IP, Zapadnjuk VI, Zaharija EA, et al. Laboratornye zhivotnye, Kiev, 1983: 383 p.

Poltorak VV, Gorbenko NI. Doklinichni doslidzhennja likars’kyh zasobiv, za red. Stefanova OV, Kyi’v, 2001:396-408.

Reznikov OG. Endokrynologija 2003; 8(1):142-145.

Armitage P, Berry G. Statistical methods in medical research, Blackwell Sci Publ, 1994: 620 p.

Royston, J. Applied Statistic 1992; 31:115-124.

Atramentova L, Utjevs’ka O. Statystychni metody v biologii’: pidruchnyk, Harkiv, 2007: 288 p.

PASS, available at: www.ibmc.msk.ru/PASS. 18. Gerstein HC. Lancet 2010; 375:2195-2196.

Reaven GM. Med Clin North Am 2011; 95(5):875-892.

Downloads

Published

2014-12-08

How to Cite

Krasova, N., Gladkih, A., Lipson, V., Leshchenko, Z., Tyzhnenko, T., Opaleiko, Y., Zubatyuk, T., Svidlo, I., Yaremenko, F., & Poltorak, V. (2014). EFFECT OF POTENTIAL INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE OF TYPE 1 ON THE FUNCTIONAL-METABOLIC PARAMETERS IN RATS WITH EXPERIMENTAL TYPE 2 DIABETES MELLITUS. Problems of Endocrine Pathology, 50(4), 60-66. https://doi.org/10.21856/j-PEP.2014.4.07

Most read articles by the same author(s)